#BioSpectrum conducted this survey jointly with the Association of Biotechnology Led Enterprises (ABLE). BioSpectrum and ABLE have jointly been doing this exercise since 2003. A detailed questionnaire (survey form) was sent to over 200 companies to capture the needed information for the analysis. This was done during April-May 2013. Companies shared information with us to the extent it was possible by them.
#The revenues considered for the analysis are biotech products sales and service figures. In several cases, where revenue figures were not available, estimates were arrived in discussion with industry experts. These are denoted (*) as "BioSpectrum Estimates".
#This year in the list of Top 20 companies, biotech focused companies across the life sciences spectrum have been considered, including diagnostics space.
#Biotech suppliers' revenues are not considered/included in this analysis.
#BioPharma segment included products made by fermentation/animal cell culture (not animal extracts) and plant cell culture (not plant extracts).
#The BioAgri segment analysis includes only the GM seeds and molecular markers and related products. So, the hybrid seeds business is not a part of the agri-business sales values.
#The BioServices segment analysis includes the contract as well as clinical research services revenue.
#For all the ranking purposes, we have taken the biotech business only into consideration. Wherever 'TURNOVER' is mentioned, it means, sales turnover from biotech. Therefore, turnover wherever mentioned is not necessarily the total sales turnover of the company.